Interactive Learning
Gary M. Owens, MD
Alfonso Quintas-Cardama, MD
Atheer A. Kaddis, PharmD

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: July 15th, 2012 - July 16th, 2013

Program Description

Symptomatic burden in myelofibrosis (MF) is severe and can highly compromise quality of life. Many patients require assistance for activities of daily living or disability. Most importantly, symptomatic patients probably have a lower survival than those who are asymptomatic. The presence of debilitating constitutional symptoms, such as fatigue, bone pain, fever, pruritus, night sweats, weight loss, and cachexia, is included as a negative predictor of survival in both the IPSS and the DIPSS prognostic scoring systems. For patients with MF, progressive splenomegaly, hepatomegaly with liver failure, portal hypertension, gastrointestinal bleeding, pulmonary hypertension, infections, and malnutrition are the major complications that lead to significantly diminished quality-of-life and lower life-expectancy. Management of these complications and symptoms can be difficult and invasive and may place a tremendous burden on the healthcare system. 

Emerging therapies are changing the pathway of treatment for patients with MF. This activity will provide attendees with an in-depth understanding of the treatment strategies for patients with MF.

Learning Objectives

  • Assess clinical data demonstrating that emerging therapies provide significant and durable relief for patients with MF in terms of decreased splenomegaly and improved symptoms, and the benefit this provides for improving quality-of life
  • Identify patient- and disease-associated prognostic factors that may impact the choice of management strategy for the treatment of patients with MF
  • Evaluate the healthcare value proposition associated with emerging therapies and evolving treatment strategies for MF

Target Audience
This activity is developed for physicians, nurses, pharmacists, and managed care professionals who are involved in the care of patients with myelofibrosis.

Physician Accreditation
The Medical Learning Institute, Inc. (MLI) designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical Learning Institute, Inc. and Center of Excellence Media, LLC. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.

Registered Pharmacy Designation
Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.  Completion of this activity provides for 1.5 contact hours (0.15 CEU) of continuing education credit. 

The Universal Activity Number for this activity is 0468-9999-12-022-H01-P.

Disclosures
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent-discussed in this program should be inferred.

Planners' and Managers' Disclosures
Puthugramam Natrajan, MD, FACOG, CCD
disclosed that he is on the Speakers Bureau of Warner Chilcott
Lorrie McSherry, RN, BSN, OCN disclosed that she is on the advisory Board of Onyx
Nancy Nesser, JD, PharmD has nothing to disclose

Faculty Disclosures
Gary M. Owens, MD,
discloses that he is a consultant for Eli Lilly, Auxilium Pharmaceuticals, OncoMed, Allergan, Eyetech, and Johnson & Johnson. He also is on the advisory board or does market research for Amgen, Pfizer, and Centocor Ortho Biotech. He does not intend to discuss non-FDA-approved drugs or investigational use of any product/device.
Alfonso Quintas-Cardama, MD, discloses that he is a consultant for Bristol-Myers Squibb and Novartis. He does intend to discuss non-FDA-approved or investigational use for several JAK2 inhibitors not yet FDA approved for the treatment of myelofibrosis as well as other compounds, such as lenalidomide, interferon, histone deacetylase inhibitors.
Atheer A. Kaddis, PharmD, has nothing to disclose. He does not intend to discuss non-FDA-approved drugs or investigational use of any product/device.

Disclaimer
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent-discussed in this program should be inferred.

Related Items
New Directions in the Treatment and Symptom Management of Multiple Sclerosis – Part 2
Samuel F. Hunter, MD, PhD, Gary M. Owens, MD
Interactive Learning published on June 13, 2013
Myelofibrosis and Multiple Myeloma: Strategies for Effective Decision-Making
Martha L. Arellano, MD, Jonathan L. Kaufman, MD , James T. Kenney Jr, RPh, MBA, Gary M. Owens, MD
Supplements published on July 31, 2012
Emerging Treatments and Evolving Strategies for the Cost Effective Management of Multiple Myeloma
Jonathan L. Kaufman, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
Perspectives on Recent Clinical Practice Guideline Updates for the Management of Chemotherapy-Induced Nausea and Vomiting
Steven M. Grunberg, MD, Atheer A. Kaddis, PharmD , James J. Natale, PharmD, BCOP, Kimberly Noonan, MS, RN, ANP, AOCN
Supplements published on June 15, 2012
Optimizing New and Emerging Therapies for Treatment and Symptom Management of Multiple Sclerosis in Managed Care
Gary M. Owens, MD, Bruce L. Hughes, MD , Sonya J. Lewis, RPh, MBA
Supplements published on August 2, 2011
Wellness and Prevention in Chronic Disease Consensus Statement
Gary M. Owens, MD, Nirav R. Shah, MD, MPH, FACP, Michael McLean, RPh, MPA, Kip Piper, MA, FACHE, Doug Burgoyne, PharmD, John Fox, MD, Stacie Heller, Wayne M. Lednar, MD, PhD, Lynne Rothney-Kozlak, Scott R. Taylor, RPh, MBA, F. Randy Vogenberg, RPh, PhD
Supplements published on September 30, 2010
Highlights from ASCO 2010: An Update for Payers and Providers on Chronic Myelogenous Leukemia
Gary M. Owens, MD, Michael Mauro, MD
Supplements published on September 15, 2010
Health System/Regional Variations in the Delivery of Care for Multiple Myeloma
Gary M. Owens, MD, Jatin Shah, MD, Rusty Crawford, RPh, BCOP, Sin (Masha) Lam, PharmD, BCOP, Stephanie S. Minich, PharmD, BCOP
Supplements published on March 30, 2010
ASCO 2009 Highlights on Breast Cancer: A Payer's and Pharmacist's Perspective
Gary M. Owens, MD
Supplements published on September 15, 2009
Value-Based Oncology Benefit Design™ Balancing Cost, Quality, and Access in Cancer Care
Gary M. Owens, MD, Al B. Benson III, MD, FACP, Gary Rice, RPh, MS, MBA
Supplements published on June 30, 2009
Last modified: March 28, 2014